Thalidomide responsiveness in an infant with Behcet's syndrome

Pediatrics

Volumn 103, Issue 6 I, 1999, Pages 1295-1297

  Shek, Lynette Pei Chi ^a   Lee, Yoke Sun ^a   Lee, Bee Wah ^a   Lehman, Thomas Joseph Anjorge ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Behcet's syndrome; Mouth ulcers; Thalidomide; Vasculitis

Indexed keywords

THALIDOMIDE;

APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDICATION; ENTERITIS; FEMALE; GENITAL ULCER; HUMAN; INFANT; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UVEITIS; VASCULITIS;

BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0344849511     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.6.1295     Document Type: Article

References (22)

1. Behçet H. Uber rezidivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152
2. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behçet's disease. J Rheumatol. 1992;19:1572-1574
3. Ozdagan H. Behçet's syndrome in children. Rheumatology in Europe. 1994;23(suppl 2):34
4. Jorizzo JL, Schmalsteig FC, Solomon AR, et al. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Arch Intern Med. 1986;146: 878-881
5. Ozdagan H. Behçet's syndrome in children. In: Ansell BM, Bacon PA, Lie JT, Yazici, eds. The Vasculitides. London, England: Chapman and Hall Medical; 1996:417-424
6. Mangelsdorf HC, White WL, Jorizzo JL. Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol. 1996;34(5, part 1):745-750
7. Satoshi F, Tomoko S. Behçet's disease in children: a nationwide retrospective survey in Japan. Acta Paediatr Jpn. 1997;39:285-289
8. Hashkes PJ. Recognition of infantile-onset multisystem inflammatory disease as a unique entity. J Pediatr. 1997;130:513-515
9. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-1080
10. Hamza M. Juvenile Behçet's disease. In: Wechsler B, Godeau P, eds. Behçet's Disease. Amsterdam, The Netherlands: Excerpta Medica; 1993: 377-380
11. Haslett P, Freedman VH, Kaplan G. The emerging role of thalidomide therapy in HIV-infected patients. Infect Med. 1997;14:393-398
12. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1487-1493
13. Shannon EJ, Morales MJ, Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology. 1997;35:203-212
14. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085
15. Nogueira AC, Neubert R, Helge H, et al. Thalidomide and the immune response: simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sci. 1994;55:77-92
16. Keenan RJ, Eiras G, Burckart GJ, et al. Immunosuppressive properties of thalidomide. Transplantation. 1991;52:908-910
17. Shannon EJ, Ejigu M, Haile-Mariam H, et al. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev. 1992;63:5-11
18. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-450
19. Waters MFR. An internally controlled double-blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev. 1971;42:26-42
20. Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53:828-832
21. Wulff CH, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy. Br J Dermatol. 1985;112:475-480
22. Fuller GN, Jacobs JM, Guiloff RJ. Thalidomide, peripheral neuropathy and AIDS. Int J STD AIDS. 1991;2:369-370